Črevesni mikrobiom pri bolnikih z rakom

Jakob Ivkovič (Author), Mojca Unk (Author)

Abstract

Črevesni mikrobiom predstavlja genetsko zasnovo vseh mikrobov, ki obstajajo v človeškem prebavnem traktu in vsebuje okoli 38 bilijonov mikroorganizmov, ki kodira več kot tri milijone genov. Razvoj novih tehnik molekularnega sekvenciranja je omogočil poglobljeno raziskovanje človeškega mikrobioma, ki je vpleten v presnovo hranil, zdravil, vzdržuje celovito bariero črevesne sluznice, varuje pred patogenimi mikroorganizmi in lahko spreminja imunski odziv gostitelja. Vedno več je dokazov, da je črevesni mikrobiom vpleten v razvoj nekaterih malignih bolezni in vpliva na učinkovitost onkološkega zdravljenja, predvsem na imunoterapijo. Sedanje razumevanje številnih zapletenih interakcij med črevesnim mikrobiomom, gostiteljevim imunskim sistemom, prehrano, zdravili in malignimi celicami temelji na manjših retrospektivnih in opazovalnih raziskavah. Namen tega prispevka je pregled razpoložljivih podatkov o mikrobiomu in naše dosedanje razumevanje vloge črevesnega mikrobioma pri bolnikih z rakom.

Keywords

črevesni mikrobiom;kancerogeneza;imunoterapija;zaviralci imunskih nadzornih točk;

Data

Language:	Slovenian
Year of publishing:	2024
Typology:	1.02 - Review Article
Organization:	OI - Institute of Oncology
UDC:	616-006
COBISS:	208991747
ISSN:	1408-1741
Views:	316
Downloads:	150
Average score:	0 (0 votes)
Metadata:

Other data

Secondary language:	English
Secondary title:	Gut microbiome in cancer patients
Secondary abstract:	The gut microbiome represents the genetic makeup of all the microbes in the human digestive tract. It contains about 38 trillion microorganisms with more than three million genes. With the development of new sequencing techniques, in-depth research of the human microbiome, which is involved in the metabolism of nutrients, and drugs, maintains a barrier of the intestinal mucosa, protects against pathogenic microorganisms, and can alter the host's immune response. There is compounding evidence, that the microbiome is involved in the development of certain malignant diseases and affects the effectiveness of oncological treatment, specifically on immunotherapy. Currently, the understanding of the numerous complex interactions between the gut microbiome, the host immune system, diet, drugs, and malignant cells is based on smaller retrospective and observational studies. This paper aims to review the available data on the microbiome and our current understanding of the human microbiome's role in cancer patients.
Secondary keywords:	gut microbiome;cancerogenesis;immunotherapy;immune checkpoint inhibitors;
Source comment:	Besedilo v slov.;
Pages:	str. 40-49
Volume:	ǂLetn. ǂ28
Issue:	ǂšt. ǂ2
Chronology:	dec. 2024
DOI:	10.25670/oi2024-009on
ID:	26417083